398 related articles for article (PubMed ID: 27483433)
1. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
Yoshida M; Taguchi A; Kawana K; Ogishima J; Adachi K; Kawata A; Nakamura H; Sato M; Fujimoto A; Inoue T; Tomio K; Mori M; Nagamatsu T; Arimoto T; Koga K; Hiraike OW; Oda K; Kiyono T; Osuga Y; Fujii T
Int J Oncol; 2018 Oct; 53(4):1580-1590. PubMed ID: 30066851
[TBL] [Abstract][Full Text] [Related]
3. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
Ogishima J; Taguchi A; Kawata A; Kawana K; Yoshida M; Yoshimatsu Y; Sato M; Nakamura H; Kawata Y; Nishijima A; Fujimoto A; Tomio K; Adachi K; Nagamatsu T; Oda K; Kiyono T; Osuga Y; Fujii T
BMC Cancer; 2018 Dec; 18(1):1201. PubMed ID: 30509235
[TBL] [Abstract][Full Text] [Related]
4. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
5. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
6. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells.
Motohara T; Masuko S; Ishimoto T; Yae T; Onishi N; Muraguchi T; Hirao A; Matsuzaki Y; Tashiro H; Katabuchi H; Saya H; Nagano O
Carcinogenesis; 2011 Nov; 32(11):1597-606. PubMed ID: 21828057
[TBL] [Abstract][Full Text] [Related]
7. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
8. Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78.
Mo L; Bachelder RE; Kennedy M; Chen PH; Chi JT; Berchuck A; Cianciolo G; Pizzo SV
Mol Cancer Ther; 2015 Mar; 14(3):747-56. PubMed ID: 25589495
[TBL] [Abstract][Full Text] [Related]
9. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
11. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.
Sasaki R; Narisawa-Saito M; Yugawa T; Fujita M; Tashiro H; Katabuchi H; Kiyono T
Carcinogenesis; 2009 Mar; 30(3):423-31. PubMed ID: 19126650
[TBL] [Abstract][Full Text] [Related]
13. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
14. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
15. Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.
Deng W; Gu X; Lu Y; Gu C; Zheng Y; Zhang Z; Chen L; Yao Z; Li LY
Angiogenesis; 2012 Mar; 15(1):71-85. PubMed ID: 22210436
[TBL] [Abstract][Full Text] [Related]
16. [The mouse ovarian surface epithelium cells (MOSE) transformation induced by c-myc/K-ras in].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):881-5. PubMed ID: 17533735
[TBL] [Abstract][Full Text] [Related]
17. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5.
Herr D; Sallmann A; Bekes I; Konrad R; Holzheu I; Kreienberg R; Wulff C
Gynecol Oncol; 2012 Oct; 127(1):210-6. PubMed ID: 22579791
[TBL] [Abstract][Full Text] [Related]
18. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y; Nagasaka K; Oda K; Makii C; Takeuchi M; Oki S; Honjo H; Kojima M; Miyagawa Y; Taguchi A; Tanikawa M; Sone K; Hiraike H; Matsumoto Y; Wada-Hiraike O; Ayabe T; Osuga Y; Fujii T
Cancer Sci; 2020 Oct; 111(10):3824-3834. PubMed ID: 32713096
[TBL] [Abstract][Full Text] [Related]
19. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
20. KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.
Ischenko I; Zhi J; Hayman MJ; Petrenko O
Oncotarget; 2017 Mar; 8(11):17995-18009. PubMed ID: 28152508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
